AgomAb shares surge 73.03% after-hours following $200M IPO closing and Nasdaq listing.

AgomAb Therapeutics NV (Nasdaq: AGMB) surged 73.03% in after-hours trading following the announcement of the successful closing of its initial public offering. The company raised approximately $200 million in gross proceeds by issuing 12.5 million American Depositary Shares at $16.00 per ADS, with shares beginning trading on February 6, 2026. The IPO, led by J.P. Morgan, Morgan Stanley, and other underwriters, marked Agomab’s entry into the Nasdaq Global Select Market, providing capital to advance its pipeline of disease-modifying therapies for chronic fibrotic diseases. The significant post-market rally reflects investor optimism about the company’s focus on high-unmet-need indications and the successful execution of its public offering, which underscores market confidence in its therapeutic approach and growth potential.